Patents by Inventor Fredericus A. M. Asselbergs

Fredericus A. M. Asselbergs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybrid plasminogen activator
    Patent number: 5580559
    Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: December 3, 1996
    Assignee: Ciba-Geigy Corporation
    Inventors: Bhanu Rajput, Bhabatosh Chaudhuri, Fredericus A. M. Asselbergs, Bernd Meyhack, Jutta Heim, Jan van Oostrum, Sefik Alkan
  • Pharmaceutical compositions comprising modified and unmodified plasminogen activators
    Patent number: 5409700
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of two different plasminogen activators which are used for the prophylaxis and therapie of thrombosis.
    Type: Grant
    Filed: April 7, 1993
    Date of Patent: April 25, 1995
    Assignee: Ciba-Geigy Corporation
    Inventors: Jutta Heim, Fredericus A. M. Asselbergs, Rolf Burgi
  • DNA molecules encoding hybrid proteins of tissue plasminogen activator and urokinase
    Patent number: 5242819
    Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.
    Type: Grant
    Filed: December 13, 1991
    Date of Patent: September 7, 1993
    Assignee: Ciba-Geigy Corporation
    Inventors: Bhanu Rajput, Bhabatosh Chaudhuri, Fredericus A. M. Asselbergs, Bernd Meyhack, Jutta Heim, Jan van Oostrum, Sefik Alkan